The future of gut microbiome manipulation in medicine laid out here is remarkable
sciencedirect.com/science/articl… William Fusco ElinavLab Gianluca Ianiro Giovanni Cammarota Hugh Thomas The Lancet Gastroenterology & Hepatology

The term “SOCIAL DRINKER” is too vague and should be avoided in medical records.

Few days ago I saw a patient that was described as a social drinker. He told me that he usually drinks 4-5 beers daily because: “I am a very social person”.

#medX #livertwitter

Nicoară-Farcău O et al.
Pre-emptive TIPS in high-risk acute variceal bleeding. An updated and revised individual patient data meta-analysis
#LiverTwitter
tinyurl.com/bdfau9hv

🔍 Hepatologist for a 1-year contract at our Steatotic Liver Disease Clinic. Dive into clinical research and patient care and join our team #JobOpportunity #livertwitter AISF - Associazione Italiana Studio Fegato SIGE SIMI Società Italiana Medicina Interna EASL Education apply policlinicogemelli.it/lavora-con-noi/ , Ref: PNRR-MAD-2022-12375633

Great #Gemelli #Cemad team at 2024 AISF - Associazione Italiana Studio Fegato annual meeting. In memory of Monica Moretti, the real soul of AISF - Associazione Italiana Studio Fegato

Using serum ferritin values may help predict long-term prognosis of metabolic dysfunction-associated steatotic liver disease (MASLD). Gut Journal Quentin M. Anstee Manuel Romero-Gómez Jörn Schattenberg Hannes Hagström Luca Miele Luca Valenti María Jesús pareja Dina Tiniakos

brnw.ch/21wHpc4

🎉 Excited to join forces with #GRIPonMASH !Fighting #MASH and #steatosis , our #consortium will screen 10K patients in Europe to lessen the disease burden and elevate #MASLD awareness and innovation🔬Università Cattolica #CEMAD #PoliclinicoGemelli
griponmash.eu

The most anticipated results of 2024: NASH resolution in 30%, fibrosis improvement in 25%

Resmetirom trial out now in NEJM #livertwitter

Thyroid hormone receptor beta agonist for fibrosis F1-F3

nejm.org/doi/full/10.10…

Good news for MASLD just published in the NEJM !

Resmetirom, a selective agonist of THR-β, reduces fibrosis and steatohepatitis.

Once approved, real world data will be important.

nej.md/4bHd7iT #livertwitter #MedX

Altering #BileAcid pathways as a therapeutic strategy for #CholemicNephropathy

#OpenAccess 👉bit.ly/3UBLC4b

#LiverTwitter

🔬 Interested in #MASH #NASH #NAFLD #ResearchOpportunity ? 🌟 Join our team for a 1-year #Postdoc position Università Cattolica exploring the interplay between #platelets , #Microbiome , and #NASH . Apply now!📄Learn more: progetti.unicatt.it/progetti-atene… AISF - Associazione Italiana Studio Fegato SIMI Società Italiana Medicina Interna SIGE EASL Education

📢Experts & advocates have spoken!

🚫No more 'nonalcoholic' and 'fatty'!

👏Welcome 'Metabolic Dysfunction-Associated Steatotic Liver Disease ( #MASLD )'👏

✅Embracing a variety of causes❗️

#NewNomenclature 👉bit.ly/3NSPgme

EASLnews
EASL Education

Aged patients staying overnight in the Emergency Room awaiting to be admitted have higher mortality !

I guess this probably applies to very sick patients (i.e. decompensated cirrhosis).

shorturl.at/DFR26 AASLD EASL Education #livertwitter #MedTwitter

Interesting data from NIAAA News alchepnet ⬇️ mortality & infections during #COVID era at #TLM23

Replicates our #ICU experience where likely masking & visitor (including unnecessary consults) ⬇️ nosocomial infections in #cirrhosis ⤵️
pubmed.ncbi.nlm.nih.gov/35862828/ AJG - The American Journal of Gastroenterology

1/2
📚 High burden of cirrhosis in Germany:

📈 Prevalence of 250/100,000 in 2015
🚨 > 200k patients 🏥
💔 Patients with decompensated cirrhosis face higher comorbidities, healthcare costs, and a 1-year mortality rate of 51%

🔓 bit.ly/47jvQ0Q

#livertwitter

Eric Trépo NatureRevClinOncol Juan Pablo (JP) Arab, MD  Arndt Vogel BCLC GROUP Maxime Ronot Jean-Charles Nault Jakob Nikolas Kather Maria Reig Ramon Bataller EASL Education Aleksander Krag Maja Thiele Mads Israelsen Julien Calderaro Ahmed Elsharkawy European Liver Patients' Association Russell Goodman Figures might not be exact, but screening for HCC based on etiology should be implemented.
HCC incidence in aih also extremely low journal-of-hepatology.eu/article/S0168-…

MASLD overestimated

WARNING: This cheesy reminder that #NASH is now #MASH is brought to you by the good people at #get2knowyourliver . October is Liver Awareness Month. Enjoy! #LiverTwitter AASLD Global Liver Institute Fatty Liver Foundation American Liver Foundation National youtu.be/jriS9OG98ew

Gut microbiome-derived ammonia modulates stress vulnerability in the host | Nature Metabolism nature.com/articles/s4225…

A new probiotic-guided CAR-T platform uses engineered bacteria to infiltrate and produce synthetic antigen targets, enabling CAR-T cells to find, identify, and destroy tumor cells in situ.

📄: scim.ag/4xG
#SciencePerspective : scim.ag/4xF